8-K
filed September 15, 2021, 7:59 PM ET
ticker IMVT
CIK 0001764013
leadership
confidence high
sentiment neutral
materiality 0.65
Immunovant appoints Renee Barnett as CFO; shareholders approve option repricing
Immunovant, Inc.
- Renee Barnett appointed CFO effective Oct 4, 2021; base salary $400K, signing bonus $500K, RSU bonus grant of 59,500 shares vesting Jan 1, 2022.
- Barnett also receives options for 333,000 shares and RSUs for 143,000 shares vesting over four years.
- Annual meeting results: 3 directors elected, EY ratified as auditor, say-on-pay frequency every year approved.
- Stockholders approved repricing of certain outstanding stock options under 2019 Equity Incentive Plan.
- Company plans to initiate pivotal MG trial and reinitiate TED and WAIHA programs.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.8
Eric Venker was elected as Director at Immunovant, Inc..
- Action
- elected
- Role
- Director
Exact text from the filing
Effective September 9, 2021, each of Frank M. Torti, M.D., Andrew Fromkin, Atul Pande, M.D. and Eric Venker, M.D. were elected as Series A preferred stock directors of Immunovant
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.8
Atul Pande was elected as Director at Immunovant, Inc..
- Action
- elected
- Role
- Director
Exact text from the filing
Effective September 9, 2021, each of Frank M. Torti, M.D., Andrew Fromkin, Atul Pande, M.D. and Eric Venker, M.D. were elected as Series A preferred stock directors of Immunovant
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Renee Barnett was appointed as Chief Financial Officer at Immunovant, Inc..
- Action
- appointed
- Role
- Chief Financial Officer
Exact text from the filing
On September 14, 2021, Renee Barnett was appointed the Chief Financial Officer of Immunovant, Inc. effective October 4, 2021.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.8
Andrew Fromkin was elected as Director at Immunovant, Inc..
- Action
- elected
- Role
- Director
Exact text from the filing
Effective September 9, 2021, each of Frank M. Torti, M.D., Andrew Fromkin, Atul Pande, M.D. and Eric Venker, M.D. were elected as Series A preferred stock directors of Immunovant
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.8
Frank M. Torti was elected as Director at Immunovant, Inc..
- Action
- elected
- Role
- Director
Exact text from the filing
Effective September 9, 2021, each of Frank M. Torti, M.D., Andrew Fromkin, Atul Pande, M.D. and Eric Venker, M.D. were elected as Series A preferred stock directors of Immunovant
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.